Targeted delivery of a proapoptotic peptide to tumors in vivo

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• RGD peptides target α(v)β(3) integrin, overexpressed on tumor vasculature and cells.
• RGD peptides are utilized for antiangiogenesis, tumor imaging, and drug targeting.
• Development of targeted cancer therapeutics requires precise molecular design.

Purpose of the Study:

• To design and synthesize a novel multifunctional peptide conjugate, RAFT-RGD-KLA.
• To evaluate the in vitro and in vivo efficacy of RAFT-RGD-KLA as an anti-tumor agent.
• To assess the RGD-dependent mechanism of action and potential for targeted drug delivery.

Main Methods:

• Design and synthesis of the RAFT-(c[-RGDfK-])(4) scaffold coupled to (KLAKLAK)(2) via a labile bridge.
• Incorporation of a fluorescent, activatable probe for intracellular localization.
• In vitro cytotoxicity assays on tumor cells and in vivo tumor growth inhibition studies in a mouse model.

Main Results:

• The RAFT-RGD-KLA molecule induced intracellular release of the KLA peptide at 2.5 µM.
• KLA peptide release led to mitochondrial depolarization and cell death in tumor cells in vitro.
• The peptide conjugate significantly inhibited the growth of subcutaneous tumors in a mouse model.
• Antitumor activity was confirmed to be RGD-dependent, reducing off-target toxicity.

Conclusions:

• The developed RAFT-RGD-KLA peptide conjugate is a potent anti-tumor agent.
• This targeted delivery system effectively kills cancer cells and inhibits tumor growth.
• The chemistry enables the creation of complex, multifunctional molecules for combined imaging and therapeutics.
• This represents a promising next generation of controlled, targeted drug-delivery systems for cancer treatment.